【摘要】：目的觀察鹽酸法舒地爾聯(lián)合尼莫地平治療腦外傷性蛛網(wǎng)膜下腔出血的臨床療效及安全性。方法將100例腦外傷性蛛網(wǎng)膜下腔出血患者隨機(jī)分為對(duì)照組50例與試驗(yàn)組50例。對(duì)照組予以尼莫地平注射液持續(xù)靜脈泵入,前2 h速度為0.5 mg·h~(-1),后將速度調(diào)整為1 mg·h~(-1)。試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上,給予靜脈滴注鹽酸法舒地爾注射液30 mg,qd。2組患者均連續(xù)治療2周。比較2組患者的臨床療效、腦血流速度、神經(jīng)功能評(píng)分、肝腎功能及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對(duì)照組的總有效率分別為92.00%(46/50例)和82.00%(41/50例),差異無統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組和對(duì)照組的歐洲卒中評(píng)分分別為(86.72±11.16),(75.28±10.59)分;日常生活能力評(píng)分分別為(73.27±10.05),(51.21±7.29)分,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組與對(duì)照組的大腦中動(dòng)脈血流速度分別為(79.68±11.32),(82.27±12.19)cm·s~(-1);血清谷丙轉(zhuǎn)氨酶分別為(22.78±3.06),(23.01±3.21)U·L~(-1);谷草轉(zhuǎn)氨酶分別為(23.76±3.18),(24.72±3.26)U·L~(-1);肌酸酐分別為(57.15±8.26),(56.29±8.03)μmol·L~(-1);尿素氮分別為(4.33±0.66),(4.25±0.62)mmol·L~(-1),2組比較差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。2組患者的藥物不良反應(yīng)均為頭疼、發(fā)熱、面紅,試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為12.00%和22.00%,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論鹽酸法舒地爾聯(lián)合尼莫地平治療腦外傷性蛛網(wǎng)膜下腔出血的臨床療效確切,且安全性較高。
[Abstract]:Objective to observe the clinical efficacy and safety of fasudil hydrochloride combined with nimodipine in the treatment of traumatic subarachnoid hemorrhage. Methods 100 patients with traumatic subarachnoid hemorrhage were randomly divided into control group (n = 50) and trial group (n = 50). In the control group, nimodipine injection was continuously injected intravenously, the velocity was 0.5 mg 路h ~ (- 1) at the first 2 h, and then adjusted to 1 mg 路h ~ (- 1). On the basis of the treatment in the control group, the patients in the experimental group were treated by intravenous drip of fasudil hydrochloride for 30 mg,qd.2 for 2 weeks. The clinical efficacy, cerebral blood flow velocity, neurological function score, liver and kidney function and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the experimental group and the control group were 92.00% (46 鈮，

本文編號(hào)：2474656